JP5244179B2 - （（１ｓ）−１−（（（２ｓ）−２−（５−（４’−（２−（（２ｓ）−１−（（２ｓ）−２−（（メトキシカルボニル）アミノ）−３−メチルブタノイル）−２−ピロリジニル）−１ｈ−イミダゾール−５−イル）−４−ビフェニリル）−１ｈ−イミダゾール−２−イル）−１−ピロリジニル）カルボニル）−２−メチルプロピル）カルバミン酸メチル二塩酸塩の結晶形 - Google Patents

（（１ｓ）−１−（（（２ｓ）−２−（５−（４’−（２−（（２ｓ）−１−（（２ｓ）−２−（（メトキシカルボニル）アミノ）−３−メチルブタノイル）−２−ピロリジニル）−１ｈ−イミダゾール−５−イル）−４−ビフェニリル）−１ｈ−イミダゾール−２−イル）−１−ピロリジニル）カルボニル）−２−メチルプロピル）カルバミン酸メチル二塩酸塩の結晶形 Download PDF

Info

Publication number
JP5244179B2
JP5244179B2 JP2010520184A JP2010520184A JP5244179B2 JP 5244179 B2 JP5244179 B2 JP 5244179B2 JP 2010520184 A JP2010520184 A JP 2010520184A JP 2010520184 A JP2010520184 A JP 2010520184A JP 5244179 B2 JP5244179 B2 JP 5244179B2
Authority
JP
Japan
Prior art keywords
purity
weight
type
compound
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010520184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535785A (ja
JP2010535785A5 (https=
Inventor
ソジン・キム
チ・ガオ
ヤン・フカン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5244179(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2010535785A publication Critical patent/JP2010535785A/ja
Publication of JP2010535785A5 publication Critical patent/JP2010535785A5/ja
Application granted granted Critical
Publication of JP5244179B2 publication Critical patent/JP5244179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010520184A 2007-08-08 2008-07-31 （（１ｓ）−１−（（（２ｓ）−２−（５−（４’−（２−（（２ｓ）−１−（（２ｓ）−２−（（メトキシカルボニル）アミノ）−３−メチルブタノイル）−２−ピロリジニル）−１ｈ−イミダゾール−５−イル）−４−ビフェニリル）−１ｈ−イミダゾール−２−イル）−１−ピロリジニル）カルボニル）−２−メチルプロピル）カルバミン酸メチル二塩酸塩の結晶形 Active JP5244179B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95459207P 2007-08-08 2007-08-08
US60/954,592 2007-08-08
PCT/US2008/071734 WO2009020828A1 (en) 2007-08-08 2008-07-31 Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt

Publications (3)

Publication Number Publication Date
JP2010535785A JP2010535785A (ja) 2010-11-25
JP2010535785A5 JP2010535785A5 (https=) 2011-03-31
JP5244179B2 true JP5244179B2 (ja) 2013-07-24

Family

ID=39739413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010520184A Active JP5244179B2 (ja) 2007-08-08 2008-07-31 （（１ｓ）−１−（（（２ｓ）−２−（５−（４’−（２−（（２ｓ）−１−（（２ｓ）−２−（（メトキシカルボニル）アミノ）−３−メチルブタノイル）−２−ピロリジニル）−１ｈ−イミダゾール−５−イル）−４−ビフェニリル）−１ｈ−イミダゾール−２−イル）−１−ピロリジニル）カルボニル）−２−メチルプロピル）カルバミン酸メチル二塩酸塩の結晶形

Country Status (20)

Country Link
US (1) US8629171B2 (https=)
EP (1) EP2183244B1 (https=)
JP (1) JP5244179B2 (https=)
KR (1) KR101508022B1 (https=)
CN (1) CN101778840B (https=)
AR (2) AR070016A1 (https=)
AU (1) AU2008284100B2 (https=)
BR (1) BRPI0815142B8 (https=)
CA (1) CA2695729C (https=)
CL (1) CL2008002354A1 (https=)
CO (1) CO6160327A2 (https=)
EA (1) EA018152B1 (https=)
ES (1) ES2402791T3 (https=)
IL (1) IL203684A (https=)
MX (1) MX2010001368A (https=)
NZ (1) NZ583148A (https=)
PE (1) PE20090940A1 (https=)
TW (1) TWI359813B (https=)
WO (1) WO2009020828A1 (https=)
ZA (1) ZA201000843B (https=)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009006567A2 (en) * 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
KR20100123717A (ko) 2008-02-12 2010-11-24 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
SG174883A1 (en) * 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9278922B2 (en) * 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
HUE030465T2 (hu) * 2009-05-13 2017-05-29 Antivirális vegyületek
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EA020031B1 (ru) * 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PH12012501216A1 (en) * 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
US20110152246A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
PE20130244A1 (es) 2010-01-25 2013-03-10 Enanta Pharm Inc Inhibidores del virus de la hepatitis c
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
CN102858157A (zh) 2010-03-04 2013-01-02 埃南塔制药公司 作为hcv复制的抑制剂的组合药物活性剂
CN102869657A (zh) 2010-03-24 2013-01-09 沃泰克斯药物股份有限公司 用于治疗或预防黄病毒感染的类似物
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585447A2 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
RU2452735C1 (ru) * 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR085689A1 (es) * 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012158861A2 (en) 2011-05-18 2012-11-22 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
AU2012286853A1 (en) 2011-07-26 2013-05-02 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2013217224B2 (en) 2012-02-10 2017-04-06 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
RU2507201C1 (ru) 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN106279122A (zh) * 2014-01-21 2017-01-04 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
WO2016075588A1 (en) * 2014-11-11 2016-05-19 Sun Pharmaceutical Industries Limited Stable amorphous daclatasvir dihydrochloride
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
CN104546780A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种达卡他韦薄膜包衣片制剂及其制备方法
EP3237405A1 (en) 2014-12-26 2017-11-01 Cipla Limited Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof
CN105985227A (zh) * 2015-02-06 2016-10-05 上海特化医药科技有限公司 4,4’-二卤乙酰联苯的制备及应用
CZ2015366A3 (cs) 2015-05-29 2016-12-07 Zentiva, K.S. Pevné formy Daclatasviru
WO2017006227A1 (en) * 2015-07-03 2017-01-12 Mylan Laboratories Limited Preparation process of amorphous daclatasvir dihydrochloride, amorphous solid dispersion thereof and preparation processes thereof
WO2017021904A1 (en) * 2015-08-03 2017-02-09 Laurus Labs Private Limited Daclatasvir free base and process for the preparation thereof
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105153128A (zh) * 2015-10-15 2015-12-16 上海众强药业有限公司 一种合成达卡他韦中间体的新方法
WO2017076358A1 (zh) * 2015-11-06 2017-05-11 苏州晶云药物科技有限公司 咪唑基联苯基化合物盐的新晶型及其制备方法
CN105566303A (zh) * 2016-01-25 2016-05-11 上海众强药业有限公司 达卡他韦新晶型及其制备方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN106188016A (zh) * 2016-07-04 2016-12-07 福建广生堂药业股份有限公司 盐酸达卡他韦的二水合物及其制备方法
US20190256498A1 (en) 2016-07-08 2019-08-22 Lupin Limited Crystalline forms of daclatasvir dihydrochloride
US20190337932A1 (en) * 2016-07-18 2019-11-07 Gienmark Pharmaceuticals Limited Process for preparation of daclatasvir and salts
CN106496199A (zh) * 2016-10-19 2017-03-15 上海博志研新药物技术有限公司 达卡他韦及其中间体的制备方法
CN109305962B (zh) * 2017-07-28 2022-01-18 扬子江药业集团有限公司 一种盐酸达拉他韦的精制方法
WO2019030387A1 (en) 2017-08-11 2019-02-14 Sandoz Ag SOLID COMPOSITION COMPRISING AMORPHOUS SOFOSBUVIR AND AMORPHOUS DACLATASVIR
CN108675998B (zh) * 2018-06-28 2019-08-13 北京凯因格领生物技术有限公司 一种结晶性氨基甲酸甲酯类化合物
KR102835299B1 (ko) 2018-12-04 2025-07-18 브리스톨-마이어스 스큅 컴퍼니 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors
US12497408B2 (en) 2021-05-21 2025-12-16 Gilead Sciences, Inc. Tetracyclic compounds and methods for the treatment of Zika virus infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08505854A (ja) 1993-01-14 1996-06-25 マガイニン ファーマシューティカルズ，インク． 修飾された末端を有するアミノ酸及びペプチド
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
AU2003249977A1 (en) 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1940786B1 (en) 2005-09-16 2010-08-18 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
KR20090012345A (ko) 2006-05-30 2009-02-03 애로우 쎄라퓨틱스 리미티드 바이페닐 유도체, 및 ｃ형 간염 치료에 있어서의 이들의 용도
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C

Also Published As

Publication number Publication date
US20090041716A1 (en) 2009-02-12
AU2008284100A1 (en) 2009-02-12
JP2010535785A (ja) 2010-11-25
EP2183244B1 (en) 2013-01-23
TWI359813B (en) 2012-03-11
CO6160327A2 (es) 2010-05-20
CN101778840B (zh) 2013-11-13
BRPI0815142A2 (pt) 2015-02-03
CL2008002354A1 (es) 2009-01-02
IL203684A (en) 2014-12-31
CA2695729C (en) 2015-03-31
CN101778840A (zh) 2010-07-14
ZA201000843B (en) 2011-04-28
AU2008284100B2 (en) 2014-01-16
US8629171B2 (en) 2014-01-14
WO2009020828A1 (en) 2009-02-12
BRPI0815142B8 (pt) 2021-05-25
CA2695729A1 (en) 2009-02-12
ES2402791T3 (es) 2013-05-09
EP2183244A1 (en) 2010-05-12
KR20100042641A (ko) 2010-04-26
HK1144089A1 (en) 2011-01-28
PE20090940A1 (es) 2009-07-13
AR070016A1 (es) 2010-03-10
TW200911790A (en) 2009-03-16
EA018152B1 (ru) 2013-05-30
NZ583148A (en) 2011-04-29
KR101508022B1 (ko) 2015-04-08
BRPI0815142B1 (pt) 2018-09-25
AR104566A2 (es) 2017-08-02
EA201000196A1 (ru) 2010-06-30
MX2010001368A (es) 2010-03-01

Similar Documents

Publication Publication Date Title
JP5244179B2 (ja) （（１ｓ）−１−（（（２ｓ）−２−（５−（４’−（２−（（２ｓ）−１−（（２ｓ）−２−（（メトキシカルボニル）アミノ）−３−メチルブタノイル）−２−ピロリジニル）−１ｈ−イミダゾール−５−イル）−４−ビフェニリル）−１ｈ−イミダゾール−２−イル）−１−ピロリジニル）カルボニル）−２−メチルプロピル）カルバミン酸メチル二塩酸塩の結晶形
KR101560428B1 (ko) Ｎ-(ｔｅｒｔ-부톡시카르보닐)-3-메틸-ｌ-발릴-(4ｒ)-4-((7-클로로-4-메톡시-1-이소퀴놀리닐)옥시)-ｎ-((1ｒ,2ｓ)-1-((시클로프로필술포닐)카르바모일)-2-비닐시클로프로필)-ｌ-프롤린아미드의 결정질 형태
US20060199773A1 (en) Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
IL265358A (en) Jak1 selective inhibitors and uses thereof
TR201807316T4 (tr) Bir faktör XIa inhibitörünün kristalli formları.
AU2013231052B2 (en) Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
HK1144089B (en) Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
HUE025090T2 (en) N- (tert-butoxycarbonyl) -3-methyl-L-valyl- (4R) -4 - ((7-chloro-4-methoxy-isoquinolinyl) oxy) -N- ((1R, 2S) -1 - (( cyclopropylsulfonyl) carbamoyl) 2-vinylcyclopropyl) -L-prolinamide crystalline forms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130405

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160412

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350